About this trial
The oropharyngeal areas mainly comprises of the tonsil, base tongue (BOT), soft palate and the posterior pharyngeal wall. Traditionally, surgical resection of oropharyngeal cancers (OPC) was a standard procedure, often performed through mutilating incisions with mandibulotomies, rendering significant post-operative functional deficits. Over the past 2 decades, there has been a major shift in treatment strategy with a majority of these cancers now being treated by primary concurrent chemoradiation (CCRT) with a trend towards organ and function preservation.
Eligibility criteria
Qualifiers
Histopathology proven diagnosis of squamous cell carcinoma of the oropharynx, localized to the tonsil and/or lateralized tongue-base
ECOG Performance Status ≤2
Age ≥18 to 70 years
Anesthetic fitness obtained for surgery under general anesthesia
Disqualifiers
Prior head and neck malignancy
Prior invasive malignancy, unless disease free for a minimum of 3 years
Prior chemotherapy for a different cancer administered within 3 years prior to registration
Patients who have received any neoadjuvant/ induction chemotherapy
Trial design
Treatments tested in this trial
- Surgery with or without Neck Dissection
- Radiation
- Cisplatin based chemotherpay
Treatment groups
Sponsors and collaborators
Tata Memorial Centre
Lead sponsor
All India Institute of Medical Sciences
Collaborator
Amrita Institute of Medical Sciences & Research Center
Collaborator